Loading…
Challenges in cancer vaccine development for hepatocellular carcinoma
Summary Hepatocellular carcinoma (HCC) is the most common liver malignancy, representing the third and fifth leading cause of death from cancer worldwide in men and women, respectively. The main risk factor for the development of HCC is the hepatitis B and C virus (HBV and HCV) infection; non-viral...
Saved in:
Published in: | Journal of hepatology 2013-10, Vol.59 (4), p.897-903 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c455t-b5200ce9c924cacbc91dff07deafb1587e92adb54d0fab631316fb6f696469273 |
---|---|
cites | cdi_FETCH-LOGICAL-c455t-b5200ce9c924cacbc91dff07deafb1587e92adb54d0fab631316fb6f696469273 |
container_end_page | 903 |
container_issue | 4 |
container_start_page | 897 |
container_title | Journal of hepatology |
container_volume | 59 |
creator | Buonaguro, Luigi Petrizzo, Annacarmen Tagliamonte, Maria Tornesello, Maria Lina Buonaguro, Franco M |
description | Summary Hepatocellular carcinoma (HCC) is the most common liver malignancy, representing the third and fifth leading cause of death from cancer worldwide in men and women, respectively. The main risk factor for the development of HCC is the hepatitis B and C virus (HBV and HCV) infection; non-viral causes (e.g., alcoholism and aflatoxin) are additional risk factors. HCC prognosis is generally poor because of the low effectiveness of available treatments and the overall 5-year survival rate is approximately 5–6%. In this framework, immunotherapeutic interventions, including cancer vaccines, may represent a novel and effective therapeutic tool. However, only few immunotherapy trials for HCC have been conducted so far with contrasting results, suggesting that improvements in several aspects of the immunotherapy approaches need to be implemented. In particular, identification of novel specific tumor antigens and evaluation of most advanced combinatorial strategies could result in unprecedented clinical outcomes with great beneficial effect for HCC patients. The state of the art in immunotherapy strategies for HCC and future perspectives are reported in the present review. |
doi_str_mv | 10.1016/j.jhep.2013.05.031 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1434744581</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168827813003632</els_id><sourcerecordid>1434744581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-b5200ce9c924cacbc91dff07deafb1587e92adb54d0fab631316fb6f696469273</originalsourceid><addsrcrecordid>eNp9kU2L1TAYhYMoznX0D7iQLt20vvlsCyLIZfyAARfqOqTpGyc1ba5Je2H-vSl3dOHCVTbPOUmeQ8hLCg0Fqt5MzXSHp4YB5Q3IBjh9RA5UAdSgBH1MDgXq6o613RV5lvMEABx68ZRcMd5SQWV7IDfHOxMCLj8wV36prFkspupsrPULViOeMcTTjMtauZiqcp1Zo8UQtmBSoVPB4myekyfOhIwvHs5r8v3Dzbfjp_r2y8fPx_e3tRVSrvUgGYDF3vZMWGMH29PROWhHNG6gsmuxZ2YcpBjBmUFxyqlyg3KqV0L1rOXX5PWl95Tirw3zqmef9-eYBeOWNRVctELIjhaUXVCbYs4JnT4lP5t0rynoXZ-e9K5P7_o0SF30ldCrh_5tmHH8G_njqwBvLwCWX549Jp2tx-Js9Antqsfo_9__7p-4DX7x1oSfeI95iltaij9NdWYa9Nd9wH0_yst0ijP-G9b5llA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1434744581</pqid></control><display><type>article</type><title>Challenges in cancer vaccine development for hepatocellular carcinoma</title><source>Elsevier</source><creator>Buonaguro, Luigi ; Petrizzo, Annacarmen ; Tagliamonte, Maria ; Tornesello, Maria Lina ; Buonaguro, Franco M</creator><creatorcontrib>Buonaguro, Luigi ; Petrizzo, Annacarmen ; Tagliamonte, Maria ; Tornesello, Maria Lina ; Buonaguro, Franco M</creatorcontrib><description>Summary Hepatocellular carcinoma (HCC) is the most common liver malignancy, representing the third and fifth leading cause of death from cancer worldwide in men and women, respectively. The main risk factor for the development of HCC is the hepatitis B and C virus (HBV and HCV) infection; non-viral causes (e.g., alcoholism and aflatoxin) are additional risk factors. HCC prognosis is generally poor because of the low effectiveness of available treatments and the overall 5-year survival rate is approximately 5–6%. In this framework, immunotherapeutic interventions, including cancer vaccines, may represent a novel and effective therapeutic tool. However, only few immunotherapy trials for HCC have been conducted so far with contrasting results, suggesting that improvements in several aspects of the immunotherapy approaches need to be implemented. In particular, identification of novel specific tumor antigens and evaluation of most advanced combinatorial strategies could result in unprecedented clinical outcomes with great beneficial effect for HCC patients. The state of the art in immunotherapy strategies for HCC and future perspectives are reported in the present review.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2013.05.031</identifier><identifier>PMID: 23714157</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Active immunotherapy ; Antigens, Neoplasm - immunology ; Cancer vaccine ; Cancer Vaccines - immunology ; Cancer Vaccines - therapeutic use ; Carcinoma, Hepatocellular - immunology ; Carcinoma, Hepatocellular - therapy ; Combined Modality Therapy ; Female ; Gastroenterology and Hepatology ; Hepatocellular carcinoma ; Humans ; Liver Neoplasms - immunology ; Liver Neoplasms - therapy ; Male ; Metronomic chemotherapy ; Molecular Targeted Therapy ; Tumor antigen discovery ; Tumor Microenvironment - immunology ; Vaccination - methods ; Vaccination - trends</subject><ispartof>Journal of hepatology, 2013-10, Vol.59 (4), p.897-903</ispartof><rights>European Association for the Study of the Liver</rights><rights>2013 European Association for the Study of the Liver</rights><rights>Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-b5200ce9c924cacbc91dff07deafb1587e92adb54d0fab631316fb6f696469273</citedby><cites>FETCH-LOGICAL-c455t-b5200ce9c924cacbc91dff07deafb1587e92adb54d0fab631316fb6f696469273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23714157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buonaguro, Luigi</creatorcontrib><creatorcontrib>Petrizzo, Annacarmen</creatorcontrib><creatorcontrib>Tagliamonte, Maria</creatorcontrib><creatorcontrib>Tornesello, Maria Lina</creatorcontrib><creatorcontrib>Buonaguro, Franco M</creatorcontrib><title>Challenges in cancer vaccine development for hepatocellular carcinoma</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Summary Hepatocellular carcinoma (HCC) is the most common liver malignancy, representing the third and fifth leading cause of death from cancer worldwide in men and women, respectively. The main risk factor for the development of HCC is the hepatitis B and C virus (HBV and HCV) infection; non-viral causes (e.g., alcoholism and aflatoxin) are additional risk factors. HCC prognosis is generally poor because of the low effectiveness of available treatments and the overall 5-year survival rate is approximately 5–6%. In this framework, immunotherapeutic interventions, including cancer vaccines, may represent a novel and effective therapeutic tool. However, only few immunotherapy trials for HCC have been conducted so far with contrasting results, suggesting that improvements in several aspects of the immunotherapy approaches need to be implemented. In particular, identification of novel specific tumor antigens and evaluation of most advanced combinatorial strategies could result in unprecedented clinical outcomes with great beneficial effect for HCC patients. The state of the art in immunotherapy strategies for HCC and future perspectives are reported in the present review.</description><subject>Active immunotherapy</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Cancer vaccine</subject><subject>Cancer Vaccines - immunology</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Carcinoma, Hepatocellular - immunology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Gastroenterology and Hepatology</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver Neoplasms - immunology</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Metronomic chemotherapy</subject><subject>Molecular Targeted Therapy</subject><subject>Tumor antigen discovery</subject><subject>Tumor Microenvironment - immunology</subject><subject>Vaccination - methods</subject><subject>Vaccination - trends</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9kU2L1TAYhYMoznX0D7iQLt20vvlsCyLIZfyAARfqOqTpGyc1ba5Je2H-vSl3dOHCVTbPOUmeQ8hLCg0Fqt5MzXSHp4YB5Q3IBjh9RA5UAdSgBH1MDgXq6o613RV5lvMEABx68ZRcMd5SQWV7IDfHOxMCLj8wV36prFkspupsrPULViOeMcTTjMtauZiqcp1Zo8UQtmBSoVPB4myekyfOhIwvHs5r8v3Dzbfjp_r2y8fPx_e3tRVSrvUgGYDF3vZMWGMH29PROWhHNG6gsmuxZ2YcpBjBmUFxyqlyg3KqV0L1rOXX5PWl95Tirw3zqmef9-eYBeOWNRVctELIjhaUXVCbYs4JnT4lP5t0rynoXZ-e9K5P7_o0SF30ldCrh_5tmHH8G_njqwBvLwCWX549Jp2tx-Js9Antqsfo_9__7p-4DX7x1oSfeI95iltaij9NdWYa9Nd9wH0_yst0ijP-G9b5llA</recordid><startdate>20131001</startdate><enddate>20131001</enddate><creator>Buonaguro, Luigi</creator><creator>Petrizzo, Annacarmen</creator><creator>Tagliamonte, Maria</creator><creator>Tornesello, Maria Lina</creator><creator>Buonaguro, Franco M</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20131001</creationdate><title>Challenges in cancer vaccine development for hepatocellular carcinoma</title><author>Buonaguro, Luigi ; Petrizzo, Annacarmen ; Tagliamonte, Maria ; Tornesello, Maria Lina ; Buonaguro, Franco M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-b5200ce9c924cacbc91dff07deafb1587e92adb54d0fab631316fb6f696469273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Active immunotherapy</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Cancer vaccine</topic><topic>Cancer Vaccines - immunology</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Carcinoma, Hepatocellular - immunology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Gastroenterology and Hepatology</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver Neoplasms - immunology</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Metronomic chemotherapy</topic><topic>Molecular Targeted Therapy</topic><topic>Tumor antigen discovery</topic><topic>Tumor Microenvironment - immunology</topic><topic>Vaccination - methods</topic><topic>Vaccination - trends</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buonaguro, Luigi</creatorcontrib><creatorcontrib>Petrizzo, Annacarmen</creatorcontrib><creatorcontrib>Tagliamonte, Maria</creatorcontrib><creatorcontrib>Tornesello, Maria Lina</creatorcontrib><creatorcontrib>Buonaguro, Franco M</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buonaguro, Luigi</au><au>Petrizzo, Annacarmen</au><au>Tagliamonte, Maria</au><au>Tornesello, Maria Lina</au><au>Buonaguro, Franco M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Challenges in cancer vaccine development for hepatocellular carcinoma</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2013-10-01</date><risdate>2013</risdate><volume>59</volume><issue>4</issue><spage>897</spage><epage>903</epage><pages>897-903</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><abstract>Summary Hepatocellular carcinoma (HCC) is the most common liver malignancy, representing the third and fifth leading cause of death from cancer worldwide in men and women, respectively. The main risk factor for the development of HCC is the hepatitis B and C virus (HBV and HCV) infection; non-viral causes (e.g., alcoholism and aflatoxin) are additional risk factors. HCC prognosis is generally poor because of the low effectiveness of available treatments and the overall 5-year survival rate is approximately 5–6%. In this framework, immunotherapeutic interventions, including cancer vaccines, may represent a novel and effective therapeutic tool. However, only few immunotherapy trials for HCC have been conducted so far with contrasting results, suggesting that improvements in several aspects of the immunotherapy approaches need to be implemented. In particular, identification of novel specific tumor antigens and evaluation of most advanced combinatorial strategies could result in unprecedented clinical outcomes with great beneficial effect for HCC patients. The state of the art in immunotherapy strategies for HCC and future perspectives are reported in the present review.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>23714157</pmid><doi>10.1016/j.jhep.2013.05.031</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0168-8278 |
ispartof | Journal of hepatology, 2013-10, Vol.59 (4), p.897-903 |
issn | 0168-8278 1600-0641 |
language | eng |
recordid | cdi_proquest_miscellaneous_1434744581 |
source | Elsevier |
subjects | Active immunotherapy Antigens, Neoplasm - immunology Cancer vaccine Cancer Vaccines - immunology Cancer Vaccines - therapeutic use Carcinoma, Hepatocellular - immunology Carcinoma, Hepatocellular - therapy Combined Modality Therapy Female Gastroenterology and Hepatology Hepatocellular carcinoma Humans Liver Neoplasms - immunology Liver Neoplasms - therapy Male Metronomic chemotherapy Molecular Targeted Therapy Tumor antigen discovery Tumor Microenvironment - immunology Vaccination - methods Vaccination - trends |
title | Challenges in cancer vaccine development for hepatocellular carcinoma |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T23%3A32%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Challenges%20in%20cancer%20vaccine%20development%20for%20hepatocellular%20carcinoma&rft.jtitle=Journal%20of%20hepatology&rft.au=Buonaguro,%20Luigi&rft.date=2013-10-01&rft.volume=59&rft.issue=4&rft.spage=897&rft.epage=903&rft.pages=897-903&rft.issn=0168-8278&rft.eissn=1600-0641&rft_id=info:doi/10.1016/j.jhep.2013.05.031&rft_dat=%3Cproquest_cross%3E1434744581%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c455t-b5200ce9c924cacbc91dff07deafb1587e92adb54d0fab631316fb6f696469273%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1434744581&rft_id=info:pmid/23714157&rfr_iscdi=true |